Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

38.37 -0.43 (-1.12%)

Streaming Delayed Price Updated: 11:12 AM EDT, Sep 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly Just Announced Game-Changing News ↗

Today 4:23 EDT

Something new is happening in the weight loss drug market.

Via The Motley Fool

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 27, 2026

Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.

Via The Motley Fool

Here's Where Wall Street Analysts See Eli Lilly's Share Price Going ↗

September 26, 2026

Eli Lilly's share price climb has decelerated in 2026.

Via The Motley Fool

Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become ↗

September 26, 2026

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.

Via The Motley Fool

Topics Intellectual Property

Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product? ↗

September 25, 2026

The drugmaker badly needs more clinical wins.

Via The Motley Fool

AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? ↗

September 24, 2026

Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

Via The Motley Fool

Topics Intellectual Property

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Via MarketBeat

Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? ↗

September 23, 2026

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Via MarketBeat

Topics Intellectual Property Lawsuit

Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗

September 23, 2026

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Via The Motley Fool

Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems ↗

September 22, 2026

Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?

Via The Motley Fool

Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy? ↗

September 22, 2026

Semaglutide will start losing patent protection in the near future.

Via The Motley Fool

Topics Intellectual Property

Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction ↗

September 21, 2026

Novo Nordisk A/S (NYSE:NVO) outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular...

Via MarketBeat

Why Novo Nordisk Stock Just Crashed ↗

September 21, 2026

No one expects a lot of growth from Novo Nordisk anymore -- not even Novo Nordisk itself.

Via The Motley Fool

Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗

September 17, 2026

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Via The Motley Fool

This Trend is Excellent News for Eli Lilly and Its Investors ↗

September 17, 2026

Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.

Via The Motley Fool

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗

September 16, 2026

The company is still looking to bounce back after the beating it took in recent years.

Via The Motley Fool

Topics Economy

Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything ↗

September 15, 2026

The drugmaker has a lot riding on continued clinical progress.

Via The Motley Fool

3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 ↗

September 15, 2026

These stocks have been struggling lately, but they could be underrated buys in the long run.

Via The Motley Fool

Topics Artificial Intelligence

Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 15, 2026

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.

Via The Motley Fool

Topics Regulatory Compliance

Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst ↗

September 13, 2026

Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.

Via The Motley Fool

Could This New Opportunity Be Worth Billions for Novo Nordisk? ↗

September 11, 2026

The worst may be in the rearview mirror for the drugmaker.

Via The Motley Fool

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 10, 2026

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

Via The Motley Fool

Topics Intellectual Property

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? ↗

September 10, 2026

Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.

Via The Motley Fool

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗

September 10, 2026

This company aims to serve a market heading toward $100 billion.

Via The Motley Fool

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗

September 08, 2026

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

Via The Motley Fool

Topics Intellectual Property

3 of the Best Growth Stocks to Buy for Less Than $100 Right Now ↗

September 08, 2026

Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.

Via The Motley Fool

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗

September 07, 2026

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Via The Motley Fool

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗

September 05, 2026

Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.

Via The Motley Fool

2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗

September 04, 2026

You might regret ignoring these companies at current levels.

Via The Motley Fool

Topics Artificial Intelligence

Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗

August 30, 2026

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.